Ascent Group LLC Has $1.20 Million Holdings in Becton, Dickinson and Company (NYSE:BDX)

Posted by on Mar 15th, 2023

Ascent Group LLC raised its holdings in Becton, Dickinson and Company (NYSE:BDX – Get Rating) by 35.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,090 shares of the medical instruments supplier’s stock after acquiring an additional 1,328 shares during the period. Ascent Group LLC’s holdings in Becton, Dickinson and were worth $1,201,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Fairfield Bush & CO. acquired a new position in Becton, Dickinson and in the first quarter valued at approximately $114,000. Sequoia Financial Advisors LLC lifted its stake in Becton, Dickinson and by 11.3% in the first quarter. Sequoia Financial Advisors LLC now owns 2,923 shares of the medical instruments supplier’s stock valued at $778,000 after buying an additional 297 shares during the period. Brighton Jones LLC lifted its stake in Becton, Dickinson and by 8.8% in the first quarter. Brighton Jones LLC now owns 1,383 shares of the medical instruments supplier’s stock valued at $368,000 after buying an additional 112 shares during the period. Zions Bancorporation N.A. lifted its stake in Becton, Dickinson and by 13.0% in the first quarter. Zions Bancorporation N.A. now owns 504 shares of the medical instruments supplier’s stock valued at $134,000 after buying an additional 58 shares during the period. Finally, Mather Group LLC. lifted its stake in Becton, Dickinson and by 26.0% in the first quarter. Mather Group LLC. now owns 1,346 shares of the medical instruments supplier’s stock valued at $358,000 after buying an additional 278 shares during the period. Institutional investors own 87.08% of the company’s stock.

Becton, Dickinson and Trading Up 0.6 %

Shares of Becton, Dickinson and stock opened at $232.89 on Wednesday. The stock has a fifty day simple moving average of $245.84 and a 200 day simple moving average of $241.94. Becton, Dickinson and Company has a 12-month low of $215.90 and a 12-month high of $277.29. The company has a market capitalization of $66.12 billion, a P/E ratio of 43.94, a price-to-earnings-growth ratio of 2.42 and a beta of 0.53. The company has a current ratio of 1.07, a quick ratio of 0.60 and a debt-to-equity ratio of 0.56.

Becton, Dickinson and (NYSE:BDX – Get Rating) last announced its quarterly earnings results on Thursday, February 2nd. The medical instruments supplier reported $2.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.30. The business had revenue of $4.59 billion during the quarter, compared to the consensus estimate of $4.59 billion. Becton, Dickinson and had a return on equity of 13.52% and a net margin of 8.47%. Becton, Dickinson and’s revenue was down 2.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.64 earnings per share. On average, sell-side analysts anticipate that Becton, Dickinson and Company will post 12.19 earnings per share for the current fiscal year.

Becton, Dickinson and Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 31st. Shareholders of record on Friday, March 10th will be paid a $0.91 dividend. The ex-dividend date of this dividend is Thursday, March 9th. This represents a $3.64 dividend on an annualized basis and a yield of 1.56%. Becton, Dickinson and’s dividend payout ratio (DPR) is presently 68.68%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Bank of America raised Becton, Dickinson and from a “neutral” rating to a “buy” rating and upped their target price for the stock from $250.00 to $290.00 in a research report on Tuesday, January 3rd. Evercore ISI lowered their target price on Becton, Dickinson and to $270.00 in a research report on Wednesday, November 16th. Piper Sandler upped their target price on Becton, Dickinson and from $245.00 to $260.00 and gave the stock a “neutral” rating in a research report on Thursday, February 2nd. Morgan Stanley upped their target price on Becton, Dickinson and from $290.00 to $295.00 and gave the stock an “overweight” rating in a research report on Friday, February 3rd. Finally, The Goldman Sachs Group lowered their target price on Becton, Dickinson and from $319.00 to $272.00 and set a “buy” rating on the stock in a research report on Wednesday, November 23rd. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, Becton, Dickinson and has an average rating of “Moderate Buy” and a consensus target price of $271.89.

Insider Buying and Selling at Becton, Dickinson and

In other Becton, Dickinson and news, EVP Richard Byrd sold 1,421 shares of the company’s stock in a transaction on Friday, February 3rd. The stock was sold at an average price of $248.60, for a total value of $353,260.60. Following the completion of the transaction, the executive vice president now owns 4,119 shares in the company, valued at approximately $1,023,983.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.31% of the company’s stock.

About Becton, Dickinson and

(Get Rating)

Becton, Dickinson & Co engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery.

Read More

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.